A number of other research analysts have also weighed in on MASI. Stifel Nicolaus lowered Masimo from a buy rating to a hold rating and dropped their target price for the company from $205.00 to $120.00 in a report on Tuesday, July 18th. Wells Fargo & Company dropped their target price on Masimo from $126.00 to $110.00 and set an equal weight rating on the stock in a report on Wednesday, August 9th. Needham & Company LLC restated a buy rating and issued a $136.00 target price on shares of Masimo in a report on Wednesday, August 9th. Raymond James dropped their target price on Masimo from $198.00 to $142.00 and set an outperform rating on the stock in a report on Thursday, August 10th. Finally, BTIG Research dropped their price target on Masimo from $200.00 to $153.00 in a report on Tuesday, July 18th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Hold and a consensus price target of $141.57.
Masimo Trading Down 1.2 %
Masimo (NASDAQ:MASI – Get Free Report) last announced its quarterly earnings data on Tuesday, August 8th. The medical equipment provider reported $0.62 EPS for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.24). Masimo had a net margin of 5.30% and a return on equity of 15.79%. The firm had revenue of $455.30 million during the quarter, compared to analyst estimates of $478.27 million. During the same period last year, the business posted $1.35 EPS. The company’s revenue was down 19.5% on a year-over-year basis. As a group, equities analysts anticipate that Masimo will post 3.46 earnings per share for the current fiscal year.
Institutional Trading of Masimo
Several hedge funds have recently made changes to their positions in MASI. National Bank of Canada FI bought a new stake in shares of Masimo in the second quarter valued at $29,000. Caisse DE Depot ET Placement DU Quebec bought a new stake in shares of Masimo in the first quarter valued at $37,000. Belpointe Asset Management LLC bought a new stake in shares of Masimo in the fourth quarter valued at $38,000. Achmea Investment Management B.V. purchased a new position in shares of Masimo in the second quarter valued at $39,000. Finally, Trivant Custom Portfolio Group LLC purchased a new position in shares of Masimo in the first quarter valued at $55,000. 85.96% of the stock is currently owned by institutional investors.
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and O3 regional oximetry.
- Five stocks we like better than Masimo
- Compound Interest and Why It Matters When Investing
- 5 Reasons Apple’s New Phone Moves the Needle: 5 That It Won’t
- High Dividend REITs: Are They an Ideal Way to Diversify?
- MarketBeat Week in Review – 9/11 – 9/15
- How to Effectively Use the MarketBeat Ratings Screener
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.